TSHA Stock Price, Taysha Gene Therapies Quote, Chart

Market Summary

USD2.39+0.09

Market Closed

3.91%

TSHA Stock Price

View Fullscreen

TSHA RSI Chart

TSHA Valuation

Market Cap

447.0M

Price/Earnings (Trailing)

-4.01

Price/Sales (Trailing)

28.93

Price/Free Cashflow

-5.81

TSHA Price/Sales (Trailing)

TSHA Profitability

Return on Equity

-148.88%

Return on Assets

-64.59%

Free Cashflow Yield

-17.2%

TSHA Fundamentals

TSHA Revenue

Revenue (TTM)

15.4M

Rev. Growth (Yr)

10.51%

Rev. Growth (Qtr)

-24%

TSHA Earnings

Earnings (TTM)

-111.6M

Earnings Growth (Yr)

186.68%

Earnings Growth (Qtr)

140.77%

Breaking Down TSHA Revenue

Last 7 days

5.3%

Last 30 days

-24.6%

Last 90 days

61.5%

Trailing 12 Months

258.0%

How does TSHA drawdown profile look like?

TSHA Financial Health

Current Ratio

4.08

Debt/Equity

0.54

Debt/Cashflow

-1.8

TSHA Investor Care

Shares Dilution (1Y)

194.64%

Diluted EPS (TTM)

-0.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.7M	9.0M	12.2M	15.4M
2022	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Taysha Gene Therapies Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	alam kamran	sold (taxes)	-1,944	1.51	-1,288	chief financial officer
Jan 02, 2024	alam kamran	acquired	-	-	590,413	chief financial officer
Jan 02, 2024	nagendran sukumar	acquired	-	-	863,617	president and head of r&d
Jan 02, 2024	nolan sean p.	acquired	-	-	1,184,690	chief executive officer
Nov 17, 2023	manning paul b	bought	163,000	1.63	100,000	-
Aug 24, 2023	alam kamran	sold	-76,890	2.33	-33,000	chief financial officer
Aug 16, 2023	manning paul b	bought	14,820,000	0.9	16,466,700	-
Aug 16, 2023	donenberg phillip b.	bought	99,999	0.9	111,111	-
Aug 16, 2023	nolan sean p.	bought	400,000	0.9	444,444	chief executive officer
Aug 16, 2023	stalfort john a iii	bought	350,000	0.9	388,889	-

Which funds bought or sold TSHA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-102,908	-	-%
Apr 25, 2024	Chicago Partners Investment Group LLC	reduced	-7.09	118,738	316,969	0.01%
Apr 25, 2024	Allworth Financial LP	unchanged	-	1,100	2,870	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	new	-	50,000	50,000	-%
Apr 23, 2024	Morton Brown Family Wealth, LLC	unchanged	-	286	746	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 17, 2024	Cannon Global Investment Management, LLC	new	-	69,454	69,454	0.19%
Apr 16, 2024	Williams & Novak, LLC	unchanged	-	-	79,650	0.09%
Apr 15, 2024	Capital Investment Advisors, LLC	unchanged	-	11,000	28,700	-%
Apr 12, 2024	Dynamic Advisor Solutions LLC	unchanged	-	49,050	129,150	-%

Are Funds Buying or Selling TSHA?

Are funds buying TSHA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TSHA

No. of Funds

Unveiling Taysha Gene Therapies Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	5.6%	10,412,872	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.8%	18,505,556	SC 13G
Feb 14, 2024	ra capital management, l.p.	9.99%	18,670,089	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	1.6%	2,912,861	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Aug 28, 2023	venrock healthcare capital partners iii, l.p.	7.7%	14,444,444	SC 13G
Aug 25, 2023	tcg crossover gp i, llc	5.9%	11,111,111	SC 13G
Aug 25, 2023	ra capital management, l.p.	9.99%	18,690,868	SC 13G
Aug 21, 2023	manning paul b	12.6%	23,476,333	SC 13D/A

Recent SEC filings of Taysha Gene Therapies Inc

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	ARS	ARS
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Taysha Gene Therapies Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Taysha Gene Therapies Inc News

Latest updates

Taysha Gene Therapies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Revenue	-24.0%	3,607	4,746	2,395	4,700	3,264	1,828	392
Operating Expenses	-5.5%	19,850	20,996	25,779	21,265	56,468	25,457	33,373
S&GA Expenses	-21.8%	6,719	8,589	5,988	8,751	7,341	8,683	9,867
R&D Expenses	7.6%	12,682	11,791	19,791	12,514	12,707	16,774	23,506
Interest Expenses	-51.5%	713	1,471	1,440	1,374	1,305	1,078	743
Net Income	140.8%	47,741	-117,087	-24,598	-17,622	-55,078	-26,527	-34,092
Net Income Margin	58.9%	-7.22*	-17.55*	-13.79*	-23.23*	-66.35*	-	-
Free Cashflow	10.1%	-16,134	-17,949	-18,719	-24,085	12,403	-30,830	-41,216

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-11.8%	173	196	82.00	102	126	111	142	166	214	241	242	243	259	279	-
Current Assets	-12.8%	150	172	54.00	72.00	96.00	43.00	77.00	107	160	197	207	240	258	279	0.00
Cash Equivalents	-12.4%	144	164	45.00	63.00	88.00	34.00	66.00	97.00	149	189	197	229	251	279	-
Net PPE	-3.1%	11.00	11.00	14.00	15.00	15.00	64.00	61.00	55.00	51.00	41.00	34.00	2.00	0.00	0.00	-
Liabilities	-60.1%	98.00	245	119	117	125	100	110	115	119	101	55.00	20.00	8.00	12.00	-
Current Liabilities	-79.6%	37.00	180	51.00	54.00	63.00	33.00	43.00	49.00	52.00	43.00	28.00	19.00	7.00	12.00	0.00
Long Term Debt	5.1%	41.00	39.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	28.00	-	-	-	-	-
LT Debt, Non Current	5.1%	41.00	39.00	38.00	38.00	38.00	38.00	38.00	37.00	37.00	28.00	-	-	-	-	-
Shareholder's Equity	-	75.00	-	-	-	1.00	11.00	33.00	51.00	95.00	140	186	223	251	268	-
Retained Earnings	8.5%	-513	-560	-443	-419	-401	-345	-319	-285	-235	-185	-134	-93.15	-61.13	-42.81	-1.11
Additional Paid-In Capital	14.9%	588	512	407	404	402	357	352	336	331	326	321	316	312	310	1.00
Shares Outstanding	0%	187	187	64.00	63.00	63.00	40.00	40.00	38.00	38.00	37.00	37.00	37.00	38.00	-	-
Float	-	-	-	30.00	-	-	-	92.00	-	-	-	479	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	10.2%	-16,117	-17,949	-18,767	-20,185	14,712	-28,810	-33,353	-40,939	-40,258	-31,933	-22,816	-22,035	-19,848	-6,716	-2,466	-1,699	-	-
Share Based Compensation	-3.5%	1,968	2,040	2,222	1,675	4,103	4,470	4,141	5,329	4,955	5,086	4,549	3,594	2,013	1,341	-	-	-	-
Cashflow From Investing	99.7%	-10.00	-3,490	48.00	-3,900	-2,370	-3,020	-8,113	-11,427	-8,520	-4,002	-8,498	-534	-6,051	-31.00	-3,000	-	-	-
Cashflow From Financing	-103.0%	-4,248	140,634	377	-370	41,232	-103	11,075	-107	9,105	-	-	-	-1,482	274,181	338	18,027	-	-

TSHA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 15,451	$ 2,502
Operating expenses:
Research and development	56,778	91,169
General and administrative	30,047	37,360
Impairment of long-lived assets	1,065	36,420
Total operating expenses	87,890	164,949
Loss from operations	(72,439)	(162,447)
Other income (expense):
Change in fair value of warrant liability	(34,718)
Loss on debt extinguishment	(1,398)
Change in fair value of term loan	(1,538)
Interest income	3,572	249
Interest expense	(4,998)	(3,798)
Other expense	(47)	(18)
Total other expense, net	(39,127)	(3,567)
Net loss	$ (111,566)	$ (166,014)
Net loss per common share, basic	$ (0.96)	$ (3.78)
Net loss per common share, diluted	$ (0.96)	$ (3.78)
Weighted average common shares outstanding, basic	116,121,482	43,952,015
Weighted average common shares outstanding, diluted	116,121,482	43,952,015

TSHA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 143,940	$ 87,880
Restricted cash	449
Prepaid expenses and other current assets	3,479	8,537
Assets held for sale	2,000
Total current assets	149,868	96,417
Restricted cash	2,151	2,637
Property, plant and equipment, net	10,826	14,963
Operating lease right-of-use assets	9,582	10,943
Other non-current assets	304	1,316
Total assets	172,731	126,276
Current liabilities
Accounts payable	6,366	10,946
Accrued expenses and other current liabilities	12,284	18,287
Deferred revenue	18,106	33,557
Total current liabilities	36,756	62,790
Term loan, net	40,508	37,967
Operating lease liability, net of current portion	18,953	20,440
Other non-current liabilities	1,577	4,130
Total liabilities	97,794	125,327
Commitments and contingencies - Note 13
Stockholders' equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and December 31, 2022
Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 186,960,193 issued and outstanding as of December 31, 2023 and 200,000,000 shares authorized and 63,207,507 issued and outstanding as of December 31, 2022.	2	1
Additional paid-in capital	587,942	402,389
Accumulated deficit	(513,007)	(401,441)
Total stockholders’ equity	74,937	949
Total liabilities and stockholders' equity	$ 172,731	$ 126,276

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

CEO	Mr. Sean P. Nolan
WEBSITE	tayshagtx.com
INDUSTRY	Biotechnology
EMPLOYEES	65

Taysha Gene Therapies Inc Frequently Asked Questions

What is the ticker symbol for Taysha Gene Therapies Inc? What does TSHA stand for in stocks?

TSHA is the stock ticker symbol of Taysha Gene Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Taysha Gene Therapies Inc (TSHA)?

As of Fri Apr 26 2024, market cap of Taysha Gene Therapies Inc is 446.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSHA stock?

You can check TSHA's fair value in chart for subscribers.

What is the fair value of TSHA stock?

You can check TSHA's fair value in chart for subscribers. The fair value of Taysha Gene Therapies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Taysha Gene Therapies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TSHA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Taysha Gene Therapies Inc a good stock to buy?

The fair value guage provides a quick view whether TSHA is over valued or under valued. Whether Taysha Gene Therapies Inc is cheap or expensive depends on the assumptions which impact Taysha Gene Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSHA.

What is Taysha Gene Therapies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TSHA's PE ratio (Price to Earnings) is -4.01 and Price to Sales (PS) ratio is 28.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSHA PE ratio will change depending on the future growth rate expectations of investors.